Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this project is to evaluate the effects of the anticonvulsant drug lamotrigine (trade name Lamictal) on neuropathic facial pain or neuralgia using functional magnetic resonance imaging (fMRI).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pain and Analgesia Imaging and Neuroscience Group
• Collaborator: GlaxoSmithKline
• Treatments: Anticonvulsants; Lamotrigine

Criteria

Inclusion Criteria:

• 18-60 years of age

• Right-handed non-smokers

• Diagnosed with facial pain

• Continuous pain for more than 3 months

• Spontaneous pain greater than 3 of 10

• Allodynia to brush greater than 5 of 10

Exclusion Criteria:

• Medications

• Depression

• Significant medical problems

• Claustrophobia

• Abnormal EKG

• Significant drug or alcohol history

• Positive drug screen

• Weight greater than 285 lbs

• History of allergy to anticonvulsants

• Tattoos with metallic ink on upper body

• Any neurostimulator devices, or metal cochlear, ocular, or cardiac implants or other metal near vital areas

• Exposure to shrapnel or metal filings

• Other metallic surgical hardware